A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer

This early-phase study is testing a new drug called INV-9956 for men with advanced prostate cancer that has stopped responding to hormone therapy (called castrate-resistant prostate cancer). Researchers want to learn whether the drug is safe, how the body processes it, and whether it has any anti-cancer effects. **You may be eligible if...** - You are a male aged 18 or older - You have prostate cancer that has spread to other parts of the body - Your cancer is no longer responding to hormone-reducing treatments (testosterone levels below 50 ng/dL) - You have already received at least one hormone-targeted therapy (such as abiraterone or enzalutamide) - You are in reasonably good health with adequate organ function - You have a life expectancy of more than 3 months **You may NOT be eligible if...** - You have significant uncontrolled medical conditions - You cannot swallow oral medications - Your blood clotting, liver, or kidney function falls outside acceptable ranges Talk to your doctor to see if this trial is right for you.